Please assess the completion status of the following clinical trial:

Trial Title: Cross-Over Study in Subjects With COPD, Evaluating Lung Function Response After Treatment With Once Daily Umeclidinium 62.5mcg, Vilanterol 25mcg, and Umeclidinium/Vilanterol 62.5/25mcg

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Type of Patient: Outpatient~* Informed Consent: A signed and dated written informed consent prior to study participation~* Age: Subjects 40 years of age or older at Visit 1~* Gender: Male or female subjects.~* COPD diagnosis: As defined by the American Thoracic Society/European Respiratory Society (ATS/ERS)~* Severity of disease: A pre- and post-salbutamol FEV1/FVC ratio of \<0.70 and a pre- and post-salbutamol FEV1 of ≤ 70% of predicted normal values at Visit 1~* Smoking History: Current or former cigarette smokers with a history of cigarette smoking of ≥ 10 pack-years at Visit 1~* Female subject of non child-bearing potential OR a female subject of child bearing potential, with a negative pregnancy test at screening, and agreeing to consistently and correctly use one of the acceptable contraceptive methods~Exclusion Criteria:~* Pregnancy: Women who are pregnant or lactating or are planning on becoming pregnant during the study~* Asthma: A current diagnosis of asthma~* Other Respiratory Disorders: Known alpha-1 antitrypsin deficiency, active lung infections (such as tuberculosis), and lung cancer are absolute exclusionary conditions.~* Other Diseases/Abnormalities: Subjects with historical or current evidence of clinically significant cardiovascular, neurological, psychiatric, renal, hepatic, immunological, endocrine (including uncontrolled diabetes or thyroid disease) or hematological abnormalities that are uncontrolled and/or a previous history of cancer in remission for \< 5 years prior to Visit 1~* Contraindications: A history of allergy or hypersensitivity to any anticholinergic/muscarinic receptor antagonist, beta2-agonist, lactose/milk protein or magnesium stearate or a medical condition such as of narrow-angle glaucoma, prostatic hypertrophy or bladder neck obstruction that, in the opinion of the study physician contraindicates study participation or use of an inhaled anticholinergic.~* Hospitalization: Hospitalization for COPD or pneumonia within 12 weeks prior to Visit 1.~* Lung Resection: Subjects with lung volume reduction surgery within the 12 months prior to Visit 1.~* 12-Lead ECG: An abnormal and significant ECG finding from the 12-lead ECG conducted at Visit 1~* Screening Labs: Significantly abnormal finding from clinical chemistry or hematology tests at Visit 1 as determined by the study investigator.~* Medication Prior to Spirometry: Unable to withhold salbutamol for the 4 hour period required prior to spirometry testing at each study visit and at each spirometry test performed at home.~* Medications Prior to Screening: Use of the prohibited medications according to defined time intervals prior to Visit 1~* Oxygen: Use of long-term oxygen therapy (LTOT) described as oxygen therapy prescribed for greater than 12 hours a day. As-needed oxygen use (i.e., ≤ 12 hours per day) is not exclusionary.~* Nebulized Therapy: Regular use (prescribed for use every day, not for as-needed use) of short-acting bronchodilators (e.g., salbutamol, ipratropium bromide) via nebulized therapy~* Pulmonary Rehabilitation Program: Participation in the acute phase of a pulmonary rehabilitation program within 4 weeks prior to Visit 1. Subjects who are in the maintenance phase of a pulmonary rehabilitation program are not excluded.~* Drug or Alcohol Abuse: A known or suspected history of alcohol or drug abuse within 2 years prior to Visit 1.~* Affiliation with Investigator Site: Is an investigator, sub-investigator, study coordinator, employee of a participating investigator or study site, or immediate family member of the aforementioned that is involved in this study.~* Inability to read: In the opinion of the Investigator, any subject who is unable to read and/or would not be able to complete a questionnaire

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Umeclidinium/Vilanterol 62.5/25 mcg (Type: EXPERIMENTAL): Umeclidinium/Vilanterol 62.5/25 mcg once daily in the morning via novel dry powder inhaler (NDPI)
- Umeclidinium 62.5 mcg (Type: EXPERIMENTAL): Umeclidinium 62.5 mcg once daily in the morning via novel dry powder inhaler (NDPI)
- Vilanterol 25 mcg (Type: EXPERIMENTAL): Vilanterol 25 mcg once daily in the morning via novel dry powder inhaler (NDPI)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete